Novel compound heterozygous mutations of CLDN16 in a patient with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
11 2020
Historique:
received: 13 06 2020
revised: 13 07 2020
accepted: 04 08 2020
pubmed: 2 9 2020
medline: 8 6 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive tubulopathy characterized by excessive urinary wasting of magnesium and calcium, bilateral nephrocalcinosis, and progressive chronic renal failure in childhood or adolescence. FHHNC is caused by mutations in CLDN16 and CLDN19, which encode the tight-junction proteins claudin-16 and claudin-19, respectively. Most of these mutations are missense mutations and large deletions are rare. We examined the clinical and biochemical features of a Spanish boy with early onset of FHHNC symptoms. Exons and flanking intronic segments of CLDN16 and CLDN19 were analyzed by direct sequencing. We developed a new assay based on Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) to investigate large CLDN16 deletions. Genetic analysis revealed two novel compound heterozygous mutations of CLDN16, comprising a missense mutation, c.277G>A; p.(Ala93Thr), in one allele, and a gross deletion that lacked exons 4 and 5,c.(840+25_?)del, in the other allele. The patient inherited these variants from his mother and father, respectively. Using direct sequencing and our QMPSF assay, we identified the genetic cause of FHHNC in our patient. This QMPSF assay should facilitate the genetic diagnosis of FHHNC. Our study provided additional data on the genotypic spectrum of the CLDN16 gene.

Sections du résumé

BACKGROUND
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive tubulopathy characterized by excessive urinary wasting of magnesium and calcium, bilateral nephrocalcinosis, and progressive chronic renal failure in childhood or adolescence. FHHNC is caused by mutations in CLDN16 and CLDN19, which encode the tight-junction proteins claudin-16 and claudin-19, respectively. Most of these mutations are missense mutations and large deletions are rare.
METHODS
We examined the clinical and biochemical features of a Spanish boy with early onset of FHHNC symptoms. Exons and flanking intronic segments of CLDN16 and CLDN19 were analyzed by direct sequencing. We developed a new assay based on Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) to investigate large CLDN16 deletions.
RESULTS
Genetic analysis revealed two novel compound heterozygous mutations of CLDN16, comprising a missense mutation, c.277G>A; p.(Ala93Thr), in one allele, and a gross deletion that lacked exons 4 and 5,c.(840+25_?)del, in the other allele. The patient inherited these variants from his mother and father, respectively.
CONCLUSIONS
Using direct sequencing and our QMPSF assay, we identified the genetic cause of FHHNC in our patient. This QMPSF assay should facilitate the genetic diagnosis of FHHNC. Our study provided additional data on the genotypic spectrum of the CLDN16 gene.

Identifiants

pubmed: 32869508
doi: 10.1002/mgg3.1475
pmc: PMC7667358
doi:

Substances chimiques

Claudins 0
claudin 16 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1475

Informations de copyright

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Pediatr Nephrol. 1987 Jul;1(3):465-72
pubmed: 3153319
Commun Biol. 2019 Mar 25;2:113
pubmed: 30937396
J Bone Miner Res. 2016 Mar;31(3):498-513
pubmed: 26426912
J Clin Invest. 2006 Apr;116(4):878-91
pubmed: 16528408
Gene. 2019 Mar 20;689:227-234
pubmed: 30576809
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183344
pubmed: 32442419
J Clin Invest. 2008 Feb;118(2):619-28
pubmed: 18188451
PLoS One. 2013;8(1):e53151
pubmed: 23301036
Hum Mutat. 2017 Sep;38(9):1092-1108
pubmed: 28508593
J Cell Biol. 1999 Dec 13;147(6):1351-63
pubmed: 10601346
Clin J Am Soc Nephrol. 2012 May;7(5):801-9
pubmed: 22422540
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W306-10
pubmed: 15980478
Bioinformatics. 2016 Jul 15;32(14):2230-2
pubmed: 27193693
World J Pediatr. 2015 Aug;11(3):272-5
pubmed: 25410674
Kidney Int. 1995 May;47(5):1419-25
pubmed: 7637271
Am J Hum Genet. 2003 Dec;73(6):1293-301
pubmed: 14628289
Eur J Hum Genet. 2015 Jun;23(6):
pubmed: 25182135
Science. 2014 Apr 18;344(6181):304-7
pubmed: 24744376
Invest Ophthalmol Vis Sci. 2011 Mar 14;52(3):1392-403
pubmed: 21071746
J Cell Sci. 2005 Nov 1;118(Pt 21):5109-18
pubmed: 16234325
BMC Nephrol. 2015 Jul 02;16:92
pubmed: 26136118
Bioinformatics. 2018 Feb 1;34(3):511-513
pubmed: 28968714
Sci Rep. 2016 Sep 20;6:33632
pubmed: 27647526
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Clin Kidney J. 2015 Dec;8(6):656-64
pubmed: 26613020
Am J Hum Genet. 2006 Nov;79(5):949-57
pubmed: 17033971
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Mol Genet Genomic Med. 2020 Nov;8(11):e1475
pubmed: 32869508
Genes (Basel). 2020 Mar 10;11(3):
pubmed: 32164158
J Am Soc Nephrol. 2001 Sep;12(9):1872-81
pubmed: 11518780
Proteins. 2006 Mar 1;62(4):1125-32
pubmed: 16372356
J Med Genet. 2017 Jan;54(1):26-37
pubmed: 27530400
J Am Soc Nephrol. 2008 Jan;19(1):171-81
pubmed: 18003771
Science. 1999 Jul 2;285(5424):103-6
pubmed: 10390358

Auteurs

Alejandro García-Castaño (A)

Biocruces Bizkaia Research Institute, Barakaldo, Bizkaia, Spain.

Ana Perdomo-Ramirez (A)

Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Mònica Vall-Palomar (M)

Fisiopatologia Renal, Centro de Investigaciones en Bioquímica y Biología Molecular (CIBBIM), Vall d'Hebron Institut de Recerca (VHIR, Barcelona, Spain.

Elena Ramos-Trujillo (E)

Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Leire Madariaga (L)

Biocruces Bizkaia Research Institute, Barakaldo, Bizkaia, Spain.
Pediatric Nephrology Department, Cruces University Hospital, UPV/EHU, Barakaldo, Spain.

Gema Ariceta (G)

Fisiopatologia Renal, Centro de Investigaciones en Bioquímica y Biología Molecular (CIBBIM), Vall d'Hebron Institut de Recerca (VHIR, Barcelona, Spain.
Servicio de Nefrología Pediátrica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Departamento de Pediatría, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain.

Felix Claverie-Martin (F)

Unidad de Investigación, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH